Celltrion (068270) Fundamentals 2026 — P/E 30.4x, Revenue Analysis | SniperIQ
Celltrion (068270) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩39.01T, trading at ₩170100.00 on the KSC. This SniperIQ fundamentals page covers Celltrion's valuation (P/E 30.4x, P/B 2.2x), profitability (net margin 28.4%), revenue (₩4.16T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Celltrion's market cap?
Celltrion (068270) has a market capitalization of approximately ₩39.01T, trading at ₩170100.00 on the KSC. Market cap moves with the live share price.
What is Celltrion's P/E ratio?
Celltrion's trailing twelve-month P/E ratio is 30.4x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Celltrion?
Celltrion runs a net profit margin of 28.4%, a gross margin of 59.9%, and an operating margin of 29.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Celltrion generate?
Celltrion reported revenue of ₩4.16T for fiscal year 2025, with net income of ₩1.03T and earnings per share (EPS) of 4466.05. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Celltrion pay a dividend?
Celltrion offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Celltrion financially healthy?
Celltrion carries a debt-to-equity ratio of 0.22x and a current ratio of 1.39x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Celltrion a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Celltrion (068270) the key facts are: market cap ₩39.01T, P/E 30.4x, revenue ₩4.16T, 52-week range 158500-239047.62. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Celltrion's full fundamentals live
Get Celltrion's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.